Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis-Reference-Cited by-同舟云学术

Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis

Published:2018-09-07 Issue:11 Volume:35 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Iriyama Noriyoshi^ORCID,Sugimoto Kei-Ji,Sato Eriko,Takaku Tomoiku,Tokuhira Michihide,Nakazato Tomonori,Ishikawa Maho,Fujita Hiroyuki,Fujioka Isao,Kimura Yuta,Asou Norio,Kizaki Masahiro,Komatsu Norio,Hatta Yoshihiro,Kawaguchi Tatsuya

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s12032-018-1203-7/fulltext.html

Reference24 articles.

1. Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376:917–27.

2. Tauchi T, Kizaki M, Okamoto S, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res. 2011;35:585–90.

3. Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27:107–12.

4. Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91:869–74.

5. Kantarjian HM, Cortes JE, Kim DW, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123:1309–18.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study;Clinical Lymphoma Myeloma and Leukemia;2024-06

2. BiCNN-CML: Hybrid Deep Learning Approach for Chronic Myeloid Leukemia;2022 5th International Conference on Contemporary Computing and Informatics (IC3I);2022-12-14

3. Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia;International Journal of Hematologic Oncology;2022-06

4. Expression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukaemia patients during the first year of imatinib therapy;Gene;2022-03

5. Protective effect of a new heterocyclic compound on acute tracheobronchitis via reducing IL-6 and TNF-α content and PKA-NF-κB pathway activation;Main Group Chemistry;2021-05-10